Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

161. Osteoporosis: Diagnosis, Treatment and Fracture Prevention

Osteoporosis: Diagnosis, Treatment and Fracture Prevention Osteoporosis: Diagnosis, Treatment and Fracture Prevention - Province of British Columbia theme_3_collection theme_3_frontend theme_3_collection theme_3_frontend Birth, Adoption, Death, Marriage & Divorce theme_1_collection theme_1_frontend theme_1_collection theme_1_frontend British Columbians & Our Governments theme_data_collection data_frontend theme_data_collection data_frontend Data theme_5_collection theme_5_frontend (...) theme_10_collection theme_10_frontend Sports, Recreation, Arts & Culture theme_8_collection theme_8_frontend theme_8_collection theme_8_frontend Taxes & Tax Credits theme_14_collection theme_14_frontend theme_14_collection theme_14_frontend Tourism & Immigration Search default_collection default_frontend Section Navigation Osteoporosis: Diagnosis, Treatment and Fracture Prevention Effective Date: May 1, 2011 Revised: October 1, 2012 Recommendations and Topics Scope Osteoporosis (OP) is a significant risk factor

2013 Clinical Practice Guidelines and Protocols in British Columbia

162. Effectiveness of Teriparatide Therapy for Prevention of Fractures in Glucocorticoid-Induced Osteoporosis

Effectiveness of Teriparatide Therapy for Prevention of Fractures in Glucocorticoid-Induced Osteoporosis "Effectiveness of Teriparatide Therapy for Prevention of Fractures in G" by Tristan T. Stiles < > > > > > Title Author Date of Graduation Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, PA-C, MS Second Advisor Eric Foote, PA-C, MS Third Advisor Mark Pedemonte, MD Rights . Abstract Background (...) : Glucocorticoids have a wide-range of beneficial effects for treating inflammatory, allergic, and immunologic conditions. However, glucocorticoid therapy can lead to increased bone resorption and reduced bone formation by inhibiting osteoblast proliferation. This bone deterioration leads to osteoporosis. When considering therapy for prevention of fractures in glucocorticoid-induced osteoporosis (GIO), teriparatide (recombinant human parathyroid hormone 1-34) is an anabolic agent that can be used to improve

2013 Pacific University EBM Capstone Project

163. Osteoporosis: Prevention and Treatment

Osteoporosis: Prevention and Treatment 5 Quality Department Guidelines for Clinical Care Ambulatory Osteoporosis Guideline Team Team Lead Robert W. Lash, MD Endocrinology Team Members R. Van Harrison, PhD Medical Education Jane T. McCort, MD General Medicine Jane M. Nicholson, MD Obstetrics/Gynecology Lourdes Velez, MD Family Medicine Initial Release March, 2002 Most Recent Major Update July, 2010 Interim/Minor Revision June, 2013 Ambulatory Clinical Guidelines Oversight Connie J Standiford, MD (...) presented by the patient. Osteoporosis: Prevention and Treatment Patient population: Postmenopausal women and persons at risk for secondary osteoporosis related to long-term glucocorticoid use, organ transplant, or other medical conditions. Objective: Decrease osteoporotic fractures and their associated morbidity and mortality. Key Points Definitions Bone mineral density [BMD] correlates with skeletal strength and fracture risk. Dual-energy X-ray absorptiometry [DXA] measures BMD. A DXA T-score

2013 University of Michigan Health System

164. Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause

Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause Drug Approval Package: Duavee NDA #022247 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Duavee (conjugated estrogens and bazedoxifene) Company: Wyeth Pharmaceuticals, Inc. Application No.: 022247 Approval Date: 10/3/2013 Persons with disabilities having problems accessing

2013 FDA - Drug Approval Package

165. Transition to osteoporosis for 10% of women takes 17?years for those with normal bone density, 5?years for those with moderate osteopenia: implications for the frequency of bone density testing

Transition to osteoporosis for 10% of women takes 17?years for those with normal bone density, 5?years for those with moderate osteopenia: implications for the frequency of bone density testing Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate osteopenia: implications for the frequency of bone density testing | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate osteopenia: implications for the frequency of bone density testing Article Text Electronic pages Transition to osteoporosis for 10% of women takes 17 years for those with normal bone density, 5 years for those with moderate osteopenia: implications for the frequency of bone density testing John Adam Robbins Statistics from Altmetric.com Commentary on: Gourlay ML , Fine JP

2013 Evidence-Based Medicine (Requires free registration)

166. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. (Full text)

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Osteoporosis medications increase bone-mineral density (BMD) and lower but do not eliminate fracture risk. The combining of anabolic agents with bisphosphonates has not improved efficacy. We compared combined teriparatide and denosumab with both agents alone.From September, 2009, to January, 2011, we enrolled postmenopausal women with osteoporosis into this randomised

2013 Lancet PubMed

167. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment (Full text)

Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment Nayak S, Roberts MS, Greenspan SL Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study investigated the effect of various generic alendronate costs on the cost-effectiveness of osteoporosis screening and treatment in women aged 65 years and older. The authors concluded that osteoporosis screening followed by alendronate treatment provided value-for-money across a wide range of alendronate costs compared with no screening

2013 NHS Economic Evaluation Database. PubMed

168. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted business products Purchase ADA products Access oral-health (...) information for the public and ADA Find-A-Dentist Partnerships and Commissions Learn about ADA CERP recognition, look up CERP recognized CE providers and find CE courses. Explore CODA's role and find accredited schools and programs Learn about the examinations used in licensing dentists and dental hygienists Learn about recognized dental specialties and certifying boards Evidence Education * Associated Topics Relationship between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate

2012 ADA Center for Evidence-Based Dentistry

169. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted business products Purchase ADA products Access oral-health (...) information for the public and ADA Find-A-Dentist Partnerships and Commissions Learn about ADA CERP recognition, look up CERP recognized CE providers and find CE courses. Explore CODA's role and find accredited schools and programs Learn about the examinations used in licensing dentists and dental hygienists Learn about recognized dental specialties and certifying boards Evidence Education * Associated Topics Relationship between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate

2012 ADA Center for Evidence-Based Dentistry

170. Relationship between osteoporosis and periodontitis still unclear

Relationship between osteoporosis and periodontitis still unclear Relationship between osteoporosis and periodontitis still unclear ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage of endorsed, discounted business products Purchase ADA products Access oral-health (...) information for the public and ADA Find-A-Dentist Partnerships and Commissions Learn about ADA CERP recognition, look up CERP recognized CE providers and find CE courses. Explore CODA's role and find accredited schools and programs Learn about the examinations used in licensing dentists and dental hygienists Learn about recognized dental specialties and certifying boards Evidence Education * Associated Topics Relationship between osteoporosis and periodontitis still unclear Joan Leakey Clinical Associate

2012 ADA Center for Evidence-Based Dentistry

171. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials Han SL, Wan SL CRD summary This review found that teriparatide was effective (...) in the treatment of postmenopausal osteoporosis, with reductions in risks of fracture and improvements in bone mineral density. Although the quality of the studies was generally low, the authors' conclusions are likely to be reliable. Authors' objectives To evaluate the efficacy of teriparatide in reducing the risk of fractures and improving bone mineral density in postmenopausal women with osteoporosis. Searching PubMed, Cochrane Central Register of Controlled Trials (CENTRAL) and ISI Web of Knowledge were

2012 DARE.

172. Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial

Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial Vol 20. DTB: Vol 20, No 2. March - April 2012 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DTB: Vol 20, No 2. March - April 2012 DTB: Vol 20, No 2. March - April 2012 Content tools Share it Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial Denosumab has shown efficacy vs placebo in the reduction of morphometric

2012 Drug and Therapeutics Bulletin of Navarre (Spain)

173. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines

Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines CADTH Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Denosumab and zoledronic acid for patients with postmenopausal osteoporosis: a review of the clinical effectiveness, safety, cost effectiveness, and guidelines . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Denosumab and zoledronic acid were shown to be safe

2012 Health Technology Assessment (HTA) Database.

174. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms

Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Gauthier K, Bai A, Perras C, Cunningham J, Ahuja T, Richter T, Kovacs C. Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis: clinical effectiveness and harms. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012 Authors' conclusions Evidence from six placebo-controlled randomized

2012 Health Technology Assessment (HTA) Database.

175. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report

Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Crandall CJ, Newberry SJ, Gellad WG, Diamant A, Lim YW, Suttorp M, Motala A, Ewing B, Roth B, Timmer M, Shanman R, Shekelle PG. Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review

2012 Health Technology Assessment (HTA) Database.

176. Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis. (PubMed)

Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis. 22986396 2012 12 03 2012 09 18 1539-3704 157 6 2012 Sep 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis. JC3-4 10.7326/0003-4819-157-6-201209180-02004 Johnson Bruce E BE eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 Int J Clin Pract. 2012 Feb;66(2):199-209 22257045 2012 9 19 6 0 2012 9

2012 Annals of Internal Medicine

177. Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis (Full text)

Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis Kingkaew P, Maleewong U, Ngarmukos C, Teerawattananon Y (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of strategies of systematic screening for osteoporosis among postmenopausal women and medical treatments for those diagnosed positive. The authors

2012 NHS Economic Evaluation Database. PubMed

178. Denosumab and Zoledronic Acid for Patients with Postmenopausal Osteoporosis: A Review of the Clinical Effectiveness, Safety, Cost Effectiveness, and Guidelines

Denosumab and Zoledronic Acid for Patients with Postmenopausal Osteoporosis: A Review of the Clinical Effectiveness, Safety, Cost Effectiveness, and Guidelines Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH (...) and used for non-commercial purposes, provided that attribution is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Denosumab and Zoledronic Acid for Patients with Postmenopausal Osteoporosis: A Review of the Clinical Effectiveness, Safety, Cost Effectiveness, and Guidelines

2012 Canadian Agency for Drugs and Technologies in Health - Rapid Review

179. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis (PubMed)

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis The aim of this study was to perform a head-to-head comparison of efficacy and safety profile between 60 mg denosumab (Den) subcutaneously (SC) per 6 months (Q6M) and 70 mg alendronate (Aln) orally per week (QW) for postmenopausal women with low bone mineral density. We searched electronic databases comparing efficacy and safety of Den SC Q6M and Aln QW

2012 EvidenceUpdates

180. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials (PubMed)

Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials To determine the efficacy of teriparatide supplementation for improving bone mineral density (BMD) and fracture risk in postmenopausal osteoporosis and if effects vary with factors. We identified eight randomised controlled trials (n = 2388) using electronic databases, supplemented by a hand-search of the reference lists. All trials aimed to evaluate (...) the efficacy of daily subcutaneous teriparatide injection in postmenopausal osteoporosis. The main outcomes were fracture risk and percentage change of BMD from baseline. Data were pooled by employing a random-effect model. In trials that reported BMD as an outcome, treatment was associated with an increase of bone mass of 8.14% [95% confidence interval (CI): 6.72-9.55%; eight trials, n = 2206] in spine and 2.48% (95% CI: 1.67-3.29%; seven trials, n = 1303) at the hip. In trials that reported fracture

2012 EvidenceUpdates